Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 22, 2025, by Bioaffinity Technologies, Inc., a Delaware corporation and emerging growth company. The report details a corporate governance event concerning the Company's wholly-owned subsidiary, Precision Pathology Laboratory Services LLC ("PPLS"), and its relationship with Village Oaks Pathology Services, P.A. ("Village Oaks Pathology").
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a succession agreement and does not contain financial statements.
Material Changes
The primary material event reported is the transfer of 100% of the issued and outstanding stock of Village Oaks Pathology from Dr. Roby P. Joyce to Dr. James Humphreys. Key details include:
- Succession Event: On December 22, 2025, a new Succession Agreement was executed between Village Oaks Pathology, PPLS, and Dr. Humphreys.
- Reason for Transfer: Dr. Joyce (age 77) voluntarily initiated the transfer. The filing explicitly states this was not due to any disagreement with the Company or PPLS, nor was it due to Dr. Joyce failing to meet eligibility requirements.
- Restrictions: Dr. Humphreys is restricted from disposing of his equity interests without prior written consent from the Company and Village Oaks Pathology.
- Automatic Transfer Provisions: The agreement mandates the automatic transfer of Dr. Humphreys' equity to a qualified successor in the event of his death, disability, retirement, incompetence, failure to meet eligibility requirements, Medicare disqualification, criminal conviction, bankruptcy, or material breach of the agreement.
- Successor Selection: In the event of an automatic transfer, the Village Oaks Pathology board shall nominate three candidates. The Company retains the right to reject these candidates and appoint a different qualified physician.
Outlook, Risks, and Management Commentary
Management commentary indicates a commitment to business continuity. Under the new agreement, Dr. Humphreys is obligated not to cause any voluntary interruption of Village Oaks Pathology's operations and must use commercially reasonable efforts to preserve all rights, privileges, and franchises, including contracts and licenses. The filing does not disclose specific forward-looking guidance, new risks, or unusual items beyond the standard succession mechanics.
Investor Verification Checklist
- Verify the terms of the "Management Services Agreement" referenced in the filing to understand ongoing operational obligations.
- Confirm the specific "Eligibility Requirements" for a Designated Physician as defined in the new Humphreys Succession Agreement.
- Review the Company's previous 8-K filed on September 18, 2023, to understand the original Asset Purchase Agreement and the initial Joyce Succession Agreement.
- Monitor future filings for any updates regarding the automatic transfer triggers or the nomination of successor candidates.